Daily Digest: Last 9 Hours: Stroke Risk From Recreational Drugs and DEA Scheduling Actions — March 08, 2026
March 08, 2026 — 12 articles reviewed
This cycle was dominated by a single large Cambridge study linking recreational drug use, including cannabis, to significantly elevated stroke risk, especially in younger populations. Alongside that clinical signal, a wave of DEA scheduling actions targeting novel synthetic opioids rounded out a regulatory-heavy news period.
The Cambridge stroke data deserves a permanent place in every clinician’s cannabis counseling toolkit, particularly for younger patients who assume plant-based means risk-free. Screen broadly, counsel specifically, and remember that good medicine means weighing cardiovascular signals just as seriously as we weigh the benefits.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
